Kang Ting, Beverly Hills, CA (US); and B. Chia Soo, Beverly Hills, CA (US)
Assigned to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on May 10, 2021, as Appl. No. 17/315,593.
Application 15/265,680 is a division of application No. 13/256,931, granted, now 9,447,155, issued on Sep. 20, 2016, previously published as PCT/US2010/028540, filed on Mar. 24, 2010.
Application 17/315,593 is a continuation of application No. 15/954,225, filed on Apr. 16, 2018, granted, now 11,000,570.
Application 15/954,225 is a continuation of application No. 15/265,680, filed on Sep. 14, 2016, granted, now 9,974,828, issued on May 22, 2018.
Claims priority of provisional application 61/163,297, filed on Mar. 25, 2009.
Prior Publication US 2022/0016206 A1, Jan. 20, 2022
1. A method of increasing bone formation or regeneration at a bone fracture site in a subject in need thereof, the method comprising increasing the concentration of a polypeptide at the bone fracture site by administering a nucleic acid encoding the polypeptide, wherein the polypeptide comprises a naturally occurring human, rat, or mouse neural epidermal growth factor-like (EGFL)-like-1 (Nell-1) polypeptide that extends from the beginning of the first chordin-like cysteine-rich domain to the end of the fifth chordin-like cysteine-rich domain, wherein the polypeptide lacks the N-terminal thrombospondin-1 (TSP1) domain of a naturally occurring Nell-1 polypeptide.